Delta 9 Cannabis (TSXV:NINE) released its financial report for the second quarter of its fiscal 2018, which ended on June 30.

As quoted in the press release:


  • Revenues of C$715,746 and C$1,047,853 – up 277 percent and 210 percent respectively – for the 3 month and 6 month period ending June 30, 2018 versus the same period in the prior year
  • Gross Profit of C$663,440 and C$866,135 – up 172 percent and 215 percent respectively – for the 3 month and 6 month period ending June 30, 2018, versus the same period in the prior year
  • The Company made a C$3,000,000 Investment to acquire 50 per cent of the 70,000 square foot Delta West cannabis production facility in Calgary, Alberta, which it operates in partnership with Westleaf Cannabis, primarily to supply the cannabis market in Alberta
  • The Company signed a 2,300 [kilograms] supply agreement with the Manitoba Provincial Government
  • The Company came to terms on a C$12,000,000 credit facility with a Tier 1 Canadian chartered bank, providing Delta 9 with additional capital for operations and expansion. The closing of such credit facility remains subject to due diligence
  • The Company signed a Memorandum of Understanding with US biotech firm Nanosphere Health Sciences ceding the Master License in Canada for Nanosphere’s patented delivery system for cannabis
  • The Company is currently completing work necessary to acquire the European Union “Good Manufacturing Practices” (GMP) Certification in order to initiate exports of medical cannabis to Germany
  • The Company executed its option to acquire the land on which its current facility is located, as well as neighbouring property, giving Delta 9 the capacity to expand to more than 2 million square feet

Click here to read the full press release.


Agreement propels development of safe and effective proprietary products and formulations for the emerging psychedelic industry

Optimi Health Corp. (CSE: OPTI) (“Optimi” or the “Company”), developers of a vertically integrated functional mushroom brand focused on the health and wellness sector, is pleased to announce that effective January 4, 2021, it entered into a lab services agreement with Numinus Wellness Inc. (“Numinus“). Recognized as an early leader in developing and supporting the safe, evidence-based, accessible use of psychedelic-assisted psychotherapies (PAP), Numinus is aiding Optimi’s mission to further the research and development of Canadian-grown psilocybin-producing mushrooms and related product formulations.

Keep reading... Show less

Nextleaf Solutions Ltd. (CSE: OILS) (OTCQB: OILFF) (“Nextleaf”, “OILS”, or the “Company”), the world’s most innovative cannabis processor, is pleased to provide shareholders with the following corporate update:

Nextleaf Comments on Financial Results from Q1 Financials

Keep reading... Show less

Hill Street Beverage Company Inc. (TSXV: BEER) (“Hill Street” or the “Company”) reported its second quarter results for the period ended December 31, 2020. A complete set of financial statements and Management’s Discussion & Analysis has been filed at All dollar figures are quoted in Canadian dollars.

The second quarter of FY21, saw continued momentum for the Company despite ongoing pandemic related challenges. Net revenue grew 8% to $745,748 from $689,276 versus the same quarter year ago. The Company also saw significant improvement on its bottom line, reducing its net loss by 50% from ($.956) million to ($.481) million, year over year for the quarter, as a result of improved gross margin and cost management efforts. On December 9, 2020, the company announced the closing of the acquisition of substantially all of the assets of Lexaria Canpharm (“Canpharm“), the cannabis products division of Lexaria Biosciences, resulting in the addition of a new B2B Line of Business.

Keep reading... Show less

Royalty Model Provides Access to Early Stage Licenced U.S. Cannabis Companies and Leverage to High-Margin Revenues

FinCanna Capital Corp. (“FinCanna” or the “Company”) (CSE:CALI), a royalty company for the licensed U.S. cannabis industry, is pleased to provide a corporate update further to its recently announced upsized financing of $2 million

Keep reading... Show less

Significant progress made as Numinus-sponsored PRIME study on psilocybin-assisted psychotherapy for opioid, stimulant and/or alcohol use disorders enters pre-implementation stage

Numinus Wellness Inc. (“Numinus” or the “Company”) (TSXV: NUMI), a company creating an ecosystem of health solutions centered around developing and supporting the safe, evidence-based, accessible use of psychedelic-assisted psychotherapies (PAP), and Syreon Corporation (Syreon), a global contract research organization with expertise in conducting clinical trials across a broad range of diseases, are pleased to share that significant progress has been made in the single-arm, open-label compassionate access 1 trial of Psilocybin-Research Intervention with Motivational Enhancement (PRIME) for substance use disorders. Currently in the development stage, the PRIME study will assess the efficacy and safety of psilocybin-assisted motivational enhancement therapy.

Keep reading... Show less